Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Apr;1(2):129-36.
doi: 10.1016/S2213-2600(13)70006-7. Epub 2013 Feb 1.

The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study

Harvey O Coxson  1 , Asger Dirksen  2 , Lisa D Edwards  3 , Julie C Yates  3 , Alvar Agusti  4 , Per Bakke  5 , Peter Ma Calverley  6 , Bartolome Celli  7 , Courtney Crim  3 , Annelyse Duvoix  8 , Paola Nasute Fauerbach  9 , David A Lomas  8 , William Macnee  10 , Ruth J Mayer  11 , Bruce E Miller  11 , Nestor L Müller  9 , Stephen I Rennard  12 , Edwin K Silverman  7 , Ruth Tal-Singer  11 , Emiel Fm Wouters  13 , Jørgen Vestbo  14 ; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators
Affiliations
Clinical Trial

The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study

Harvey O Coxson et al. Lancet Respir Med. 2013 Apr.

Abstract

Background: Emphysema is a key contributor to airflow limitation in chronic obstructive pulmonary disease (COPD) and can be quantified using CT scanning. We investigated the change in CT lung density in a longitudinal, international cohort of patients with COPD. We also explored the potential relation between emphysema and patient characteristics, and investigated if certain circulating biomarkers were associated with decline in CT lung density.

Methods: We used a random coefficient model to assess predictors of both CT lung density and its longitudinal change over 3 years in 1928 patients with COPD enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Lung density was measured for every voxel in the CT scan and after correcting for lung volume was expressed as the density at lowest 15th percentile point of the distribution. This study is registered with ClinicalTrials.gov, number NCT00292552.

Findings: Lung density at baseline was influenced by age, sex, body-mass index, current smoking status and smoking history, and severity of airflow limitation. The observed decline in lung density was variable (mean decline -1·13 g/L [SE 0·06] per year). The annual decline in lung density was more rapid in women (additional -0·41 [SE 0·14] g/L per year, p=0·003) than men and in current smokers (additional -0·29 [SE 0·14] g/L per year, p=0·047) than in former smokers. Circulating levels of the biomarkers surfactant protein D (SP-D) and soluble receptor for advanced glycation endproduct (sRAGE) were significantly associated with both baseline lung density and its decline over time.

Interpretation: This study shows that decline in lung density in COPD can be measured, that it is variable, and related to smoking and gender. We identified potential biochemical predictors of the presence and progression of emphysema.

Funding: GlaxoSmithKline.

PubMed Disclaimer

Comment in

MeSH terms

Substances

Associated data